Bavarian Nordic gains approval of vaccine production facility  

Danish biopharmaceutical company Bavarian Nordic's production facility in Denmark has been given manufacturing authorisation by the Danish Medicines Agency

Danish biopharmaceutical company Bavarian Nordic's production facility in Kvistgård, north of Copenhagen, has been given manufacturing authorisation according to the Medicines Act by the Danish Medicines Agency. The authorisation enables Bavarian Nordic to manufacture, analyse and release sterile vaccines for use in humans in accordance with full EU cGMP [current good manufacturing practice – Ed] requirements.

"Peter Wulff, president and CEO of Bavarian Nordic says: "The authorisation of our Kvistgård facility is an important milestone for Bavarian Nordic in our efforts to initiate large-scale commercial production of smallpox vaccines".

Bavarian Nordic was founded in 1994 and has operations in Denmark, Germany, the US and Singapore. The company's patented MVA-BN technology is one of the world's safest, multivalent vaccine vectors for development of vaccines against infectious diseases (smallpox and HIV) and cancer. Bavarian Nordic has ongoing development contracts with the US government to develop Imvamune as a safe third-generation smallpox vaccine. Collaboration partners include GlaxoSmithKline, Pharmexa, Impfstoffwerk Dessau-Tornau and Vaccine Solutions.

The news was reported in a Bavarian Nordic press release.

Link > Bavarian Nordic 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×